10 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has declined 61.6% per year over the past 5 years.
Operating margin has contracted, at -8058.8% in the latest year.
Financial health
The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$622489
-$47M
64.3%
-8058.8%
-$30M
—
$12M
2024
$4M
-$38M
74.5%
-1023.7%
-$30M
—
$3M
2023
$7M
-$35M
38.6%
-626.9%
-$23M
—
$15M
2022
$34M
-$14M
84.0%
-78.8%
$5M
—
$23M
2021
$98M
$37M
88.2%
47.1%
$40M
—
$89M
2020
$75M
$42M
77.7%
55.9%
$27M
—
$43M
2019
$214974
-$6M
47.7%
-2741.6%
-$6M
—
$893138
2018
$39911
-$6M
76.5%
-15328.6%
-$4M
$4M
$950237
2017
$7662
-$7M
96.1%
-59567.6%
-$3M
—
$4M
2016
—
-$2M
—
—
-$1M
—
$998737
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$145954
-$9M
-32.8%
-6309.1%
-$8M
—
$8M
Dec '25
$263922
-$26M
46.0%
-10056.7%
-$6M
—
$12M
Sep '25
$145380
-$6M
81.9%
-4824.5%
-$6M
—
$11M
Jun '25
$162910
-$8M
80.3%
-4946.1%
-$9M
—
$11M
Mar '25
$50277
-$8M
57.1%
-17009.7%
-$9M
—
$2M
Dec '24
$149325
-$11M
-70.8%
-7973.9%
-$8M
—
$3M
Sep '24
$641141
-$10M
53.6%
-1596.4%
-$7M
—
$11M
Jun '24
$3M
-$8M
92.0%
-289.1%
-$5M
—
$14M
Mar '24
$467854
-$9M
49.9%
-2192.9%
-$9M
—
$23M
Dec '23
$4M
-$15M
16.5%
-332.6%
-$5M
—
$15M
Sep '23
$2M
-$6M
89.6%
-363.7%
-$6M
—
$10M
Jun '23
$197806
-$9M
-132.1%
-6063.7%
-$6M
—
$14M
Mar '23
$601957
-$6M
16.6%
-1653.0%
-$6M
—
$6M
Dec '22
$1M
-$22M
63.2%
-1863.8%
-$4M
—
$23M
Sep '22
$5M
-$1M
84.9%
-128.3%
$888274
—
$82M
Jun '22
$5M
-$3M
81.8%
-82.6%
$1M
—
$86M
Mar '22
$23M
$12M
85.5%
43.3%
$7M
—
$97M
Dec '21
$20M
$7M
87.8%
50.5%
$5M
—
$89M
Sep '21
$30M
$11M
89.0%
45.3%
$11M
—
$83M
Jun '21
$27M
$10M
90.8%
43.1%
$12M
—
$70M
Valuation over time
How the market has priced CODX against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-sales ratio has risen from 0.2× (Mar '23) to 18.8× (Jun '26).
Price / sales (P/S)
P/S
Frequently asked questions
Is CODX growing its revenue and profit?
Over the past 5 years, Co-Diagnostics, Inc.'s revenue has declined 61.6% per year. These are computed facts, not advice.
How much debt does CODX have?
As of FY2025, Co-Diagnostics, Inc. reported — of total debt against $12M of cash.
What is CODX's profit margin?
In FY2025, gross margin was 64.3%, operating margin -8058.8%, and net margin -7533.6%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.